The global immunoassay market was valued at US$ 31.5 Bn in 2022 and is estimated to grow at a CAGR of 5.0% from 2023 to 2031, reaching US$ 48.7 Bn by the end of 2031. The market is witnessing significant growth due to the increasing demand for advanced diagnostic solutions, rising prevalence of chronic and infectious diseases, and growing adoption of automated laboratory technologies. Immunoassays have become an essential component in modern healthcare diagnostics, enabling rapid and accurate detection of biomarkers, hormones, proteins, and pathogens. As healthcare systems worldwide continue to emphasize early disease detection and precision medicine, the immunoassay market is expected to maintain steady expansion throughout the forecast period.

Access our report for a comprehensive look at key insights - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19703

Market Overview

The immunoassay market has evolved rapidly with advancements in biotechnology, molecular diagnostics, and laboratory automation. Immunoassays are widely utilized in hospitals, clinical laboratories, pharmaceutical research, and point-of-care testing applications due to their high sensitivity, specificity, and efficiency. The growing burden of diseases such as cancer, cardiovascular disorders, diabetes, and infectious diseases is significantly driving the need for reliable diagnostic technologies. Additionally, increasing healthcare awareness, expanding geriatric populations, and rising healthcare expenditures are contributing to market growth. Technological innovations such as chemiluminescence immunoassays, enzyme-linked immunosorbent assays (ELISA), and multiplex testing platforms are further enhancing diagnostic capabilities and expanding the application scope of immunoassays.

Market Size and Growth

Valued at US$ 31.5 Bn in 2022, the immunoassay market is projected to reach US$ 48.7 Bn by 2031, growing at a CAGR of 5.0%. This growth is supported by the increasing adoption of diagnostic testing in both developed and emerging economies. Rising investments in healthcare infrastructure and laboratory modernization are creating strong demand for advanced immunoassay systems. The COVID-19 pandemic also accelerated awareness and utilization of immunodiagnostic technologies, reinforcing the importance of rapid and accurate testing solutions. Furthermore, pharmaceutical and biotechnology companies are increasingly relying on immunoassays during drug discovery and clinical research processes, further contributing to market expansion.

Market Segmentation

The immunoassay market can be segmented based on product type, technology, application, and end-user. By product type, the market includes reagents and kits, analyzers, and software solutions, with reagents and kits accounting for a dominant share due to recurring demand. In terms of technology, the market comprises ELISA, chemiluminescence immunoassays, fluorescence immunoassays, and radioimmunoassays, among others. Applications include infectious disease testing, oncology, endocrinology, cardiology, and autoimmune disease diagnostics. End-users primarily consist of hospitals, diagnostic laboratories, academic research institutes, and pharmaceutical companies. Growing demand for personalized medicine and decentralized testing is further influencing market segmentation trends.

Regional Analysis

Regionally, North America dominates the global immunoassay market, supported by advanced healthcare infrastructure, strong research activities, and the presence of leading diagnostic companies. Europe also represents a significant market share due to increasing healthcare spending and rising adoption of innovative diagnostic technologies. Asia-Pacific is anticipated to witness the fastest growth during the forecast period, driven by expanding healthcare access, increasing population, and rising prevalence of chronic diseases in countries such as China and India. Meanwhile, Latin America and the Middle East & Africa are emerging markets with growing opportunities due to improving healthcare infrastructure and increasing awareness about early disease diagnosis.

Competitive Landscape

The immunoassay market is highly competitive, with major players focusing on technological innovation, strategic collaborations, and product portfolio expansion to strengthen their market positions. Some of the leading companies operating in the industry include F. Hoffmann-La Roche Ltd., Danaher Corporation, Abbott Laboratories, Siemens Healthineers (Siemens AG), DiaSorin S.p.A., Sysmex Corporation, bioMerieux SA, Ortho Clinical Diagnostics, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, and Merck kGaA. These companies are continuously investing in research and development to introduce high-performance diagnostic platforms that deliver faster and more accurate results. Partnerships, acquisitions, and expansion into emerging markets remain key strategic priorities for industry participants.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453